EvoRadar
Pricing
AI BrainLabIdeasDice
2770 ideas0 HOT640 WARM2130 COLD
© 2026 Kisum GmbH·ImpressumPrivacy / DatenschutzSubprocessorsTerms / AGBCancel subscription / Verträge hier kündigenWithdraw / Vertrag widerrufen·GitHub
EvoRadar — AI-Discovered Startup Opportunitiesevoradar.ai
© 2026 Kisum GmbHevoradar.ai · Generated by EvoRadar
← BackWatch AI Discovery

Consumer Tour-Guide for FDA Q3 Decision Days (HER2+ breast cancer)

COLD✧ v816 Mar 2026

AI Thinking Process

T3 formed: Consumer tour-guide for FDA Q3 Decision Days (atacicept + ENHERTU HER2+). Buyer: motivated biopharma patient navigating FDA advisory committee decision timeline.

Outcomes4Me ($20M raised through 2024) found. Already occupies breast cancer patient advisory space with curated HER2+ pathway. Competitor scan fires.

Pivot to atacicept for IgAN (~35K US patients, rarer indication). But frequency trap fires: post-decision app has little utility after 6 months. Economics support lifestyle business only.

T3 killed: Competitor occupied (Outcomes4Me) plus frequency trap after pivot. Verdict COLD.

Kill Reason

Outcomes4Me ($20M raised through 2024) already occupies the breast cancer patient advisory space with a curated HER2+ pathway. The consumer-tour-guide pattern requires advisory whitespace, which this indication lacks.

Risk Analysis

Risk analysis available for latest engine ideas.

Loading...

Related ideas you can explore free:

COLDConsumer FCRA Employment AI Screening Dispute Tool

killed: Three compounding factors: (1) CFPB guidance (Circular 2024-06) was rescinded in 2025 — the regulatory foundation is weaker than assumed; (2) Legal void problem: until courts rule whether AI hiring tools are consumer reporting agencies under FCRA, a dispute tool is filing disputes that screening companies may legally ignore; (3) Historical near-duplicate of 'Employment Screening FCRA Dispute Kit' (20260323-crossdomain, COLD) — the CFPB guidance rescission provides a stronger kill reason than the original.

COLDCosmetics Reformulation Competitive Intelligence

killed: Template offspring of today's CPG Reformulation Intelligence Platform (G056). Same data source approach (public ingredient databases + web scraping), same mechanism (automated diff detection). Different buyer segment (cosmetics regulatory affairs vs. CPG competitive intelligence) but not a new product — a market expansion path for the same company.

COLDAI Layoff AI-Washing Evidence Service for Employment Lawyers

killed: AI-washing of layoffs may be a 2025-2026 narrative phenomenon, not a structural market. Per-lawyer frequency (5-20 AI-washing cases/year) makes SaaS unviable — per-report pricing ($500-2,000) is consulting, not software. G028 crisis signal trap applies.